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Abstract: 
The isothiourea HBTM-2.1 (5 mol%) catalyzes the asymmetric formal [2+2] cycloaddition of both 
arylacetic acids (following activation with tosyl chloride) and preformed 2-arylacetic anhydrides with 
N-sulfonyl aldimines, generating stereodefined 2,3-diaryl--amino esters (after ring-opening) and 
3,4-diaryl-anti--lactams respectively with high diastereocontrol (up to >95:5 dr) and good to 
excellent enantiocontrol. Deprotection of the N-tosyl substituent within the -lactam framework was 
possible without racemisation by treatment with SmI2. 
 
 
 
  
 
Introduction 
The -lactam motif continues to find great importance in the pharmaceutical and biochemical 
sciences as well as generating significant interest from the broader synthetic community.
1
 Their 
historically widespread role as antibacterial agents has come under increased pressure due to recent 
discoveries of bacterial strains resistant to current drugs.
2
 This challenge, coupled with their 
emerging use in non-antibacterial therapeutic areas such as serine protease inhibitors and cholesterol 
absorption inhibitors,
3
 makes the development of synthetic methods to prepare novel -lactam based 
scaffolds a valuable endeavor.
1-3
  
The most enduring synthetic route to access -lactams remains the formal [2+2] cycloaddition 
of ketenes and imines
4
 that was first reported by Staudinger in 1907.
5
 Chiral auxiliary methods were 
used historically to control the relative and absolute product configuration within this process.
6
 More 
recent approaches have detailed, amongst others,
7
 the use of chiral Lewis base catalysis,
8
 with 
pioneering work within this area initially reported by Lectka and co-workers.
9
 Using cinchona 
alkaloid derivative 2, a range of syn-3,4-disubstituted--lactams 4 was accessed in excellent yield 
(typically >90%) and with superb diastereo- and enantioselectivity (typically >90:10 dr and 99% ee), 
derived from the use of in situ generated mono-substituted ketenes and activated aldimine 1. An 
alternative two-step -lactam formation and ring-opening sequence provided both -amino amides 
and esters in moderate yield (typically 40-60%) and with excellent diastereo- and enantioselectivity 
(dr up to 14:1 and up to 96% ee) (Scheme 1). A variety of related synthetic methods has been 
investigated, predominantly through Lewis base catalyzed processes involving isolable disubstituted 
ketenes and imines. For example, Fu has used a planar chiral PPY derivative to selectively generate 
either syn- or anti--lactams using N-tosyl and N-triflyl aldimines respectively. 10  Alternatively, 
NHCs
11
 have been used by Ye
12
 and ourselves,
13
 while Kerrigan
14
 has used a chiral phosphine to 
prepare ,-disubstituted -lactams with good to excellent levels of stereocontrol. Despite these 
precedents, there remains a clear rationale for the development of synthetic methods directed towards 
the synthesis of alternative substitution patterns within the -lactam core, especially if such a process 
could be rendered both catalytic and asymmetric. 
 
Scheme 1: Lectka’s route to -lactams and -amino esters 
Following their induction as acyl transfer agents by Birman
15
 and Okamoto
16
 the use of isothioureas 
as Lewis base catalysts has seen appreciable recent growth, with a range of processes that utilize 
these catalysts having been developed.
17
  Recent work has showcased their use for the generation of 
ammonium enolates from bench stable carboxylic acids via in situ mixed anhydride formation as a 
convenient alternative to using ketenes. Within this arena, research by Romo and co-workers has 
demonstrated the versatility of these catalysts in asymmetric intramolecular -lactone formation,18,19 
while our own research has demonstrated this methodology in both intra- and intermolecular formal 
[4+2] cycloadditions.
20
 Building upon this work and that of Connon and co-workers who performed 
the functionalization of enolizable anhydrides with a bifunctional squaramide,
21
 alternative Lewis 
base mediated ester enolate equivalents have recently been reported. For example, Chi and co-
workers have utilized activated p-nitrophenyl esters as azolium enolate precursors,
22
 while we have 
used pre-formed 2-arylacetic anhydrides in ammonium enolate catalyzed cycloadditions.
23, 24
 Mindful 
of these precedents, this manuscript demonstrates the ability of isothioureas to provide facile access 
to the -lactam and -amino ester motifs via a formal intermolecular [2+2] cycloaddition between 
N-sulfonyl aldimines and ammonium enolates generated using isothiourea catalysis from a carboxylic 
acid or isolable anhydride (Scheme 2).
25
 Although referred to as formal [2+2] cycloadditions in this 
and the following manuscript, these reactions could also be described as intermolecular enolate-imine 
cyclizations or Gilman-Speeter type reactions.
26
 Notably, this methodology provides access to -
lactams with the distinct 3,4-diaryl anti-stereochemical motif,
27,28
 in contrast with the organocatalytic 
methods previously reported that often give the syn-diastereoisomer.
9-14
 
 
Scheme 2: This work: preparation of -lactams and -amino esters  
 
Results and Discussion 
Reaction Optimization: Following our previous methodology, initial studies utilized pivaloyl 
chloride as an in situ carboxylic acid activating agent, in tandem with a range of isothiourea catalysts, 
to promote the formal [2+2] cycloaddition of an ammonium enolate derived from phenylacetic acid 
and imine 8. Using achiral isothiourea DHPB 10 and chiral isothioureas 7, 11 and 12 the 
diastereoselectivity of this process was uniformly excellent (>95:5 dr anti:syn, enty 1-4), generating 
preferentially anti--lactam 9, however the yields were variable and the ee at best moderate (66% ee, 
Table 1, Entry 4). A consistent problem encountered with the use of pivaloyl chloride was the 
isolation of the -lactam, with products contaminated with pivalic anhydride that was generated in 
situ (entries 1-5). Furthermore an iPr2NEt base-catalyzed background reaction in the absence of 
i. 7 (5 mol%)
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CH2Cl2, rt
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catalyst was operative under these conditions, leading to a competitive racemic reaction process that 
leads to erosion of product ee (entry 5). To circumvent these issues associated with the use of 
pivaloyl chloride, tosyl chloride was screened as an alternative activating agent for the carboxylic 
acid. Pleasingly, a marked increase in ee was observed, and in the case of benzotetramisole 12 a 
concurrent increase in isolated yield, while maintaining the excellent levels of diastereoselectivity 
(entry 7). Further optimization via lowering of reaction temperature to 0 C was successful in 
increasing product ee at the expense of yield, whereas further reduction to 78 C was detrimental to 
both yield and ee (entries 8-9). 
 
Entry
 
Catalyst
 
Activating 
Agent
 
T/ C Time 
/h
 
dr
a 
(anti:syn)
 
Yield 
%
b 
ee %
c 
(anti)
 
1
 
10
 tBuCOCl
 
rt
 
2
 
>95:5
 
67
d 
N/A
 
2
 
7
 tBuCOCl
 
rt
 
2
 
>95:5
 
37
 d 
57
 
3
 
11
 tBuCOCl
 
rt
 
2
 
>95:5
 
89
 d 
57 (ent)
 
4
 
12
 tBuCOCl
 
rt
 
2
 
>95:5
 
67
 d 
66
 
5
 
-
 tBuCOCl
 
rt
 
2
 
>95:5
 
39
 d 
ND
 
6
 
7
 TsCl
 
rt
 
4.5
 
>95:5
 
32
 
72
 
7
 
12
 TsCl
 
rt
 
2
 
>95:5
 
77
 
85
 
8
 
12
 
TsCl
 
0
 
5
 
>95:5
 
58
 
93
 
9
 
12
 TsCl
 −78 18 >95:5 17 80 
a 
Calculated by inspection of the 
1
H NMR of the crude reaction mixture. 
b
 Isolated yield of single diastereoisomer. 
c
 ee 
Determined by HLPC analysis on a chiral stationary phase. 
d
 Yield including pivalic anhydride contaminent.   
Table 1: Optimization of reaction conditions. 
Applying these conditions to a small selection of arylacetic acids provided the corresponding 3,4-
diaryl -lactams in moderate to good yield (42-77% yield), excellent diastereoselectivity 
(exclusively >95:5 dr) and in high levels of enantioselectivity (79-88% ee) (Table 2). The relative 
configuration within -lactam 9 was assigned via a combination of nOe and coupling constant 
analysis (typically, J = 3.4 Hz),
29
 with the absolute configuration assigned by analogy to -
aminoester 17 as anti-(3S,4R).
30
 Pleasingly, previous efforts directed towards the catalytic 
asymmetric synthesis of -lactams have not provided efficient access to this anti-3,4-diaryl structural 
motif. Additionally, (thiophenyl)acetic acid could also be used in this protocol, generating 16 with 
moderate diastereo- and enantiocontrol. 
 
   
 
  
 
a 
Isolated yield of single anti-diastereoisomer (>95:5 dr). 
b
 Calculated by inspection of the 
1
H NMR of the crude reaction 
mixture. 
c
 ee Determined by HLPC analysis on a chiral stationary phase. 
d 
Combined yield of separable diastereoisomers. 
Table 2: Variation of acid component.  
Although proceeding in excellent diastereo- and good enantioselectivity, this procedure suffers from 
typically moderate and often variable product yields that were not representative of reaction 
conversion. This was rationalized as being due to the instability of the -lactam products towards 
chromatographic purification and therefore a range of in situ derivatization methods was investigated. 
In our hands, attempted ring-opening with benzylamine following formation of the -lactam, or 
reduction into the corresponding aminoalcohol, both proved unsuccessful. However, in situ sodium 
azide promoted methanolysis
31
 provided a reproducible yield of -amino ester 17 over multiple 
runs.
32 , 33
Re-evaluating a range of chiral isothiourea catalysts in this newly developed protocol 
revealed HBTM 2.1 7 to provide marginally better levels of enantioselectivity (24% yield, 83% ee) 
over 12 (30% yield, 74% ee) over the two steps.
34
 To improve the yield a further range of 
methanolysis conditions were screened (Table 3, entries 1-6). Reducing the quantity of sodium azide 
to 10 mol% had a positive effect on yield with comparable diastereo- and enantioselectivity. 
Switching to NaOMe/methanol at rt had a detrimental effect on yield but provided product in high ee, 
while lowering the reaction temperature maintained product ee and led to increased isolated yield 
(53%) of -aminoester 17.27 Finally, optimum conditions utilized the generation of methoxide in situ 
via the addition of nBuLi to methanol at 78 C, which was then added to a solution of the -lactam, 
followed by warming to rt over 1 h to effect ring-opening.  This procedure led to the formation of -
aminoester 17 in acceptable yield over two steps (62%) and with excellent diastereo- and 
enantioselectivity (>95:5 dr and 93% ee). Furthermore, under these conditions the catalyst loading 
could be lowered to 5 mol% without significant erosion of either yield or enantioselectivity (Table 3, 
Entry 8). The yields obtained over this two-step procedure are acceptable, reproducible and are 
consistent with the findings of Lectka.
9
  
 
Entry Methanolysis 
conditions 
T/ C Time 
/h 
n mol% 
(7) 
ee (%)
a
 dr
b 
(anti/syn) 
Yield 
%
c
 
1 Excess 
NaN3/MeOH 
rt 1 20 83 >95:5 24 
2 NaN3 (10 
mol%)/MeOH 
rt 4 20 85 >95:5 66 
3 NaOMe/MeOH rt 2 20 96 >95:5 40 
4 NaOMe/MeOH 0 4 20 96 >95:5 53 
5 BuLi/MeOH 78 to 
rt 
1 20 95 >95:5 62 
6 BuLi/MeOH 78 to 
rt 
2.5 20 93 >95:5 65 
7 BuLi/MeOH 78 to 
rt 
2.5 10 95 >95:5 53 
8 BuLi/MeOH 78 to 
rt 
2.5 5 92 >95:5 65 
9 BuLi/MeOH 78 to 
rt 
2.5 1 85 >95:5 44 
a 
ee Determined by HLPC analysis on a chiral stationary phase. 
b
 Calculated by inspection of the 
1
H NMR of the crude 
reaction mixture. 
c
 Isolated yield of single anti-diastereoisomer (>95:5 dr).  
Table 3: Optimization of methanolysis conditions and catalyst loading. 
-Amino Ester Series: Scope and Limitations 
A range of arylacetic acids was next tested within this protocol to probe the reaction scope. 
Tolylacetic acids proceeded with comparable yield (40-61%) to that obtained for the parent 
phenylacetic acids, albeit in lower ee (74-86% ee) (Table 4). 2-Tolylacetic acid displayed slightly 
reduced diastereoselectivity (90:10 dr, anti:syn) as did 1-naphthyl (90:10 dr, anti:syn) which is 
thought to be due to steric effects. Arylacetic acids with electron donor (-OMe) and halogen 
substituents also proved compatible in this process, proceeding with excellent diastereoselectivity 
(>95:5 dr) in all cases, with good to excellent ee (76-98% ee) and in moderate yield (43-56%). In 
certain cases the product ee could be increased to near enantiopurity via recrystallization of the -
aminoester products (18, 22) at the expense of isolated yield. Crystallization effects during 
purification of both 17 (>99% ee) and 26 (98% ee) are postulated to account for the higher than 
average ee obtained in these cases.  
 
 
 
 
  
 
   
   
 
  
   
a 
Isolated yield of single anti-diastereoisomer (>95:5 dr). 
b
 Calculated by inspection of the 
1
H NMR of the crude reaction 
mixture. 
c
 ee Determined by HLPC analysis on a chiral stationary phase. 
d 
Isolated yield of inseparable diastereoisomers. 
e
 
Isolated yield of single anti-diastereoisomer (>95:5 dr) following recrystallization. 
f
 Combined isolated yield of separable 
diastereoisomers. 
Table 4: Variation of the acid and imine components. 
Alternative aryl substituted N-sulfonyl aldimines were next evaluated in this methodology (Table 4). 
Phenyl and 2-naphthyl-substitution were well tolerated giving 29 and 30 in good dr and ee. However, 
1-naphthyl and heteroaromatic 2-furyl substituted imine (31 and 32) both proceeded with reduced 
diastereoselectivity, while the incorporation of a strongly electron withdrawing trifluoromethyl unit 
performed poorly leading to 33 in greatly reduced enantioselectivity. Variation of the N-substituent 
was briefly investigated with an N-nosyl imine providing 34 with comparable results to N-tosyl 
substitution, although N-Boc or N-PMP aldimines failed to provide any -lactam. 
2-Arylacetic anhydrides for -lactam synthesis: 
While this two-step procedure is effective at providing a range of anti-2,3-diaryl--aminoesters with 
excellent diastereocontrol and good to excellent enantiocontrol, reproducible access to the 
corresponding -lactam motif as the direct reaction product was still desired. Attention therefore 
turned to simplification of the reaction components with the aim of aiding purification, leading to the 
consideration of 2-arylacetic anhydrides (35) as alternative ammonium enolate precursors. Treatment 
of benzoic anhydride (Ar
1
 = Ph) and aldimine 8 with HBTM 2.1 7 (5 mol%) and iPr2NEt (1.5 eq) led 
to formation of the -lactam 9 that could be consistently isolated as the major reaction product, albeit 
in low yield (30%). It was postulated that this low yield was a result of competitive Claisen-type 
condensation through addition of the ammonium enolate to the phenylacetic anhydride, resulting in 
incomplete imine consumption and so moderate conversion to -lactam. Further optimization 
through dropwise addition of an increased quantity of anhydride (1.5 eq), combined with a lower 
reaction temperature (78 C), improved the yield to 74% with continued excellent 
diastereoselectivity and reasonable enantioselectivity (>95:5 dr and 79% ee), that following 
recrystallization could be isolated in 90% ee. Under these conditions a range of both 2-arylacetic 
anhydrides and imines were tested, all leading to the isolation of the parent -lactam in moderate to 
good yield (44-74% yield) (Table 5). Modification of the anhydride portion allowed the incorporation 
of a range of aryl and heteroaryl substitution, providing -lactams 9, 15, 36 and 37 with good to 
excellent diastereo- and enantiocontrol (up to >95:5 dr; ee up to 83%). A selection of other aryl-
substituted N-sulfonyl aldimines were also tolerated, giving -lactams in similar yield (47-60% yield) 
and enantioselectivity (68-92% ee), but with slightly reduced diastereoselectivity (up to 93:7 dr). 
Importantly, as opposed to the original procedure from the arylacetic acid, the use of a 2-arylacetic 
anhydride allowed consistent isolation of the -lactam heterocycle. Additionally, removal of the N-
tosyl substituent of the parent -lactam without racemisation was possible by treatment with SmI2.
35
 
 
 
  
 
 
 
  
 
a 
Dropwise addition. 
b
 Isolated yield of anti-diastereoisomer (>95:5 dr). 
c
 Calculated by inspection of the 
1
H NMR of the 
crude reaction mixture. 
d
 Determined by HLPC analysis on a chiral stationary phase. 
e
 Isolated yield of single anti-
diastereoisomer (>95:5 dr) following recrystallization.  
Table 5: Variation of the acid and imine components in reaction from a preformed homo-anhydride. 
 
Control Studies: When using the pre-made isolable arylacetic anhydrides as ammonium enolate 
precursors, slightly reduced diastereocontrol was observed in formation of the -lactam products 
when compared with the analogous example in the -amino ester series accessed directly from the 
parent acid. This observation prompted us to investigate the possibility of in situ product 
epimerization leading to enhanced diastereocontrol. To test this hypothesis, the diastereoselectivity of 
this process was monitored with time using phenylacetic acid and imine 42 (Scheme 3, Control 
Experiment 1). After short reaction times and modest conversion a dr of ca. 85:15 was observed, but 
after prolonged exposure to the reaction conditions enhanced diastereocontrol was observed (dr 95:5), 
consistent with in situ epimerization. Also, an isolated example of -lactam 39 (dr anti:syn 21:79; 
anti 90% ee; syn 52% ee) was treated at rt with iPr2NEt (1.5 eq), HBTM-2.1 7 (5 mol%) in CH2Cl2, 
generating (ent)-anti-39 (>95:5 dr, 32% ee) in quantitative yield (Scheme 3, Control Experiment 2).
36
 
This is consistent with the syn-diastereoisomer having preferentially the (3S,4S)-configuration, and 
with in situ epimerization generating ent-39 preferentially. Under identical experimental conditions, a 
sample of anti-39 (>95:5 dr, 90% ee) showed no change in dr or ee, consistent with no epimerization 
of the anti--lactam under the reaction conditions. Finally, given that the isothiourea catalyzed ring-
opening kinetic resolution of (±)-syn--lactams has been recently reported by Birman et al.37 we were 
mindful of such an effect operating within our own system. Control investigations indicated the 
potential for a moderate, but not significant, resolution effect during the ring-opening methanolysis 
step, as treatment of (±)-9 with HBTM-2.1 7 and NaOMe in MeOH gave -amino ester 17 (dr >95:5) 
in 16% ee (Scheme 3, Control Experiment 3).
38
 
  
Scheme 3: Control experiments. 
Consistent with our previous reports we propose a catalytic cycle that proceeds via generation of an 
acyl ammonium species from either mixed- or homo-anhydride 43 (Scheme 4). Deprotonation to 
generate the (Z)-enolate 45, followed by addition to the imine furnishes intermediate 46. 
Intramolecular cyclization to provide the -lactam with concurrent catalyst regeneration completes 
the cycle. The selective formation of the anti--lactam is postulated by the pre-transition state 
assembly 47 depicted below. High facial selectivity towards the Re face of enolate 45 is controlled by 
the axial orientation of the phenyl group, with a potential no*C-S stabilizing interaction or 
electrostatic stabilization rigidifying this arrangement.
39
 Addition of this enolate to the Re face of the 
imine, occupying a staggered arrangement about the forming C-C bond, would account for the 
observed anti selectivity.  
  
Scheme 4: Proposed catalytic cycle and pre-transition state assembly 
In conclusion, isothioureas catalyze the highly diastereo- and enantioselective formation of -lactams 
and -amino esters from arylacetic anhydrides or arylacetic acids and N-sulfonyl imines 
(typically >90:10 dr). Good to excellent enantioselectivity (up to >99% ee) is typically observed in 
the formation of the -amino esters, with reduced enantioselectivity but higher isolated product 
yields observed in formation of -lactams from arylacetic anhydrides.  
Experimental 
1.1 General Information 
All reactions were performed in open flask conditions with bench grade solvents. All reagents were 
obtained from commercial sources and were used without further purification. Rt (rt) refers to 
2025 °C, with temperatures of 0 °C and 78 °C obtained using ice/water and CO2(s)/acetone baths 
respectively. 
1
H NMR spectra were acquired at either 300, 400, or 500 MHz, 
13
C{
1
H} NMR spectra 
were acquired at either 75, 100, or 125 MHz, and 
19
F{
1
H} NMR spectra were acquired at either 282, 
376, or 471 MHz. Chemical shifts are quoted in parts per million (ppm) relative to the residual 
solvent peak, coupling constants, J, are quoted in Hertz (Hz). NMR peak assignments were 
confirmed using 2D 
1
H COSY, 2D 
1
H NOESY, 2D 
1
H-
13
C HMBC and 2D 
1
H-
13
C HSQC where 
necessary. Infra-red spectra were recorded as thin films using an ATR accessory. Mass spectrometry 
(m/z) data were acquired using either electrospray ionisation (ESI), electron impact (EI), chemical 
ionisation (CI), atmospheric solids analysis probe (ASAP), atmospheric pressure chemical ionisation 
(APCI) or nanospray ionisation (NSI) using a TOF mass analyser. Optical rotations were recorded 
with a path length of 1 dm and concentrations, c, are quoted in g/100 mL. All chiral HPLC traces 
were compared with an authentic racemic trace prepared using racemic 7 or DHPB 10. 
1.2 General Experimental Procedures 
General Procedure A: Asymmetric Formal [2+2] Cycloaddition of Aryl Acetic Acids and Imines 
To a stirred solution of the appropriate carboxylic acid (1 eq) in dichloromethane (0.2 M) at 0 C, 
tosyl chloride (1.5 eq) and iPr2NEt (1.5 eq) were added. The solution was stirred at 0 C for 20 min. 
The isothiourea catalyst 12 (20 mol%) and the imine (1 eq) were added followed by iPr2NEt (1.5 eq). 
The solution was then stirred at rt for 5 h, quenched using 1 M HCl (0.2 M), extracted (3 × EtOAc) 
and the combined organic layers were dried (MgSO4) and concentrated in vacuo to give the crude 
product which was purified by column chromatography under the stated conditions to give the -
lactam product. 
General Procedure B: Asymmetric Formal [2+2] Cycloaddition of Aryl Acetic Acids and Imines 
With In Situ Ring-opening 
To a stirred solution of the carboxylic acid (1 eq) in dichloromethane (0.2 M) at 0 C, tosyl chloride 
(1.5 eq) and iPr2NEt (1.5 eq) were added. The solution was stirred at 0 C for 20 min. The isothiourea 
catalyst, 7 (5 mol%) and the imine (1 eq) were added followed by iPr2NEt (1.5 eq). The solution was 
then stirred at rt for 5 h. nBuLi (2.5 M) solution in hexanes (55 eq) was added to methanol (0.2 M) at 
−78C and this solution was added by canula to the reaction mixture. After 1 hour, the reaction was 
quenched using water (0.2 M), extracted (3 × EtOAc) and the combined organic layers were dried 
(MgSO4) and concentrated in vacuo followed by purification by column chromatography under the 
stated conditions to give the -amino ester product. 
General Procedure C: Asymmetric Formal [2+2] Cycloaddition of Homoanhydrides and Imines 
To a stirred solution of the imine (1 eq) in dichloromethane (0.2 M) at −78 C, tosyl the isothiourea 
catalyst 7 (5 mol%) and iPr2NEt (1.25 eq) were added followed by the anhydride (1.5 eq) as a 
solution in dichloromethane (0.25 M) dropwise (2.3 mLh
-1
) via syringe pump. The solution was then 
warmed to rt and stirred for a further 30 min, quenched using 1 M HCl (0.2 M), extracted (3 × EtOAc) 
and the combined organic layers were dried (MgSO4) and concentrated in vacuo followed by 
purification by column chromatography under the stated conditions to give the -lactam product. 
1.3 Starting Materials 
Isothiourea catalysts 
DHPB, (±)-HBTM-2.1 (±)-7, (2S,3R)-HBTM-2.1 7 and (+)-benzotetramisole 12 were synthesized 
according to literature procedures.
15, 20d 
N-Sulfonylaldimines 
(E)-N-(4-bromobenzylidene)-4-methylbenzenesulfonamide 8, (E)-4-methyl-N-(naphthalen-2-
ylmethylene)benzenesulfonamide 42, (E)-N-benzylidene-4-methylbenzenesulfonamide S1, (E)-N-(4-
methoxybenzylidene)-4-methylbenzenesulfonamide S2, (E)-4-methyl-N-(4-
(trifluoromethyl)benzylidene)benzenesulfonamide S3, (E)-N-(furan-2-ylmethylene)-4-
methylbenzenesulfonamide S4, (E)-4-methyl-N-(naphthalen-1-ylmethylene)benzenesulfonamide S5 
and (E)-N-benzylidene-4-nitrobenzenesulfonamide S6 were all synthesized following literature 
procedures.
13, 40
 
Anhydrides 
2-phenylacetic anhydride 35, 2-(4-methoxyphenyl)acetic anhydride S7, 2-(naphthalen-2-yl)acetic 
anhydride S8 and 2-(thiophen-2-yl)acetic anhydride S9 were all synthesized following literature 
procedures.
23
 
1.4 Experimental Procedures 
(3S,4R)-4-(4-Bromophenyl)-3-phenyl-1-tosylazetidin-2-one 9  
The title compound was prepared according to General Procedure A from phenyl acetic acid (27.2 
mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 12 
(10 mg, 20 mol%, 0.04 mmol), imine 8 (70.8 mg, 0.20 mmol) and purified by chromatography (5:95-
10:90 EtOAc:Petrol) to afford the -lactam 9 as a white solid (52.7 mg, 58%); mp 60-64 C;  
−2.3 (c 1.0 in CH2Cl2); chiral HPLC analysis, Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL 
min
-1
, 211 nm, rt), tR minor: 19.4 min, tR major: 21.0 min, 93% ee; νmax (KBr)/cm
-1 
1797 (C=O), 1369 
(C-N), 1172 (R-SO2N); δH (400 MHz, CDCl3) 2.48 (3H, s, SO2ArCH3), 4.22 (1H, d, J 3.4, C(3)H), 
4.92 (1H, d, J 3.4, C(4)H), 7.04 (2H, m, ArH), 7.18 (2H, m, ArH), 7.32 (5H, m, ArH), 7.47 (2H, m, 
ArH), 7.75 (2H, m, ArH); C (100 MHz, CDCl3) 21.8 (SO2ArCCH3), 64.4. (C(3)), 65.1 (C(4)), 123.4 
(CBr), 127.3 (Ph), 127.6 (Ph), 128.1 (Ph), 128.6 (ArC), 129.3 (ArC), 130.0 (ArC), 132.2 (Ph), 132.5 
22
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(Cipso), 135.2 (Cipso), 135.6 (Cipso), 145.6 (CMe), 165.2 (C(2)); m/z (NSI
+
) 475([M+NH4]
+
, 100%); 
HRMS (NSI+) m/z [M+NH4]
+ 
calculated for C22H22BrN2O3S
+
 473.0528; found 473.0539 (−0.2 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(m-tolyl)-1-tosylazetidin-2-one 13  
The title compound was prepared according to General Procedure A from m-tolylacetic acid (30.0 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 12 (10 
mg, 20 mol%, 0.04 mmol), imine 8 (70.8 mg, 0.20 mmol) and purified by chromatography (10:90 
EtOAc:Petrol) to afford the -lactam 13 as a white solid (50.2 mg, 53%); mp 130-134 C;  −2.6 
(c 1.0 in CH2Cl2); chiral HPLC analysis, Chiralcel OD-H (20% iPrOH:hexane, flow rate 0.25 mL 
min
-1
, 211 nm, rt), tR minor: 45.0 min, tR major: 51.5 min, 79% ee; νmax (KBr)/cm
-1
 1806 (C=O), 1370 
(C-N), 1172 (R-SO2N); δH (400 MHz, CDCl3) 2.25 (3H, s, NSO2ArCH3), 2.47 (3H, s, C(3)ArCH3) 
4.15 (1H, d, J 3.4, C(3)H) 4.87 (1H, d, J 3.4, C(4)H), 6.72 (1H, s, ArH), 6.80 (1H, d, J 7.7, ArH), 
6.71 (1H, d, J 7.7, ArH), 7.18 (3H, m, ArH), 7.33 (2H, d, J 8.3, ArH), 7.46 (2H, d, J 8.4, ArH), 7.76 
(2H, d, J 8.3, ArH); C (100 MHz, CDCl3) 21.4 (NSO2ArCH3), 21.9 (C(3)ArCH3), 64.8 (C(3)), 65.3 
(C(4)), 123.3 (ArC(4)Br), 124.7 (ArC), 127.7 (ArC), 127.8 (ArC), 128.3 (ArC), 129.2 (ArC),  129.5 
(ArC), 130.2 (Cipso), 132.3 (ArC), 132.6 (ArC), 135.4 (Cipso), 135.8 (Cipso), 139.3 (Cipso), 145.7 
(NSO2ArC(4)CH3), 165.5 (C(2)); m/z (NSI
+
) 489 ([M+NH4]
+
, 100%); HRMS (NSI+) m/z [M+NH4]
+ 
calculated for C23H24BrN2O3S
+
 487.0683; found 487.0686 (0.5 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(p-tolyl)-1-tosylazetidin-2-one 14  
The title compound was prepared according to General Procedure A from p-tolylacetic acid (30.0 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 12 (10 
mg, 20 mol%, 0.04 mmol), imine 8 (70.8 mg, 0.20 mmol) and purified by chromatography (5:95 
EtOAc:Petrol) to afford the -lactam 14 as a white solid (39.3 mg, 42%); mp 40-44 C;  −2.5 (c 
1.0 in CH2Cl2); chiral HPLC analysis, Chiralcel OD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 
211 nm, rt), tR major: 13.6 min, tR minor: 16.1 min, 86% ee; νmax (KBr)/cm
-1
 1795 (C=O), 1368 (C-
N), 1158 (R-SO2N); δH (400 MHz, CDCl3) 2.31 (3H, s, C(3)ArCH3), 2.47 (3H, s, NSO2ArCH3), 4.17 
(1H, d, J 3.4, C(3)H), 4.87 (1H, d, J 3.4, C(4)H), 6.90 (2H, d, J 8.2, C(3)ArC(2)H), 7.10 (2H, d, J 8.2, 
C(3)ArC(3)H), 7.15 (2H, d, J 8.3, SO2ArC(2)H ), 7.31 (2H, d, J 8.6, C(4)ArC(2)H), 7.46 (2H, d, J 
8.5, C(4)ArC(3)H), 7.73 (2H, d, J 8.3, SO2ArC(2)H);  C (100 MHz, CDCl3) 21.3 (C(3)ArCH3), 21.9 
(NSO2ArCH3), 64.3 (C(3)), 65.4 (C(4)), 123.1 (C(4)ArC(4)), 127.3 (ArC), 127.7 (C(3)ArC(2)), 128.2 
22
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(NSO2ArC(2)), 129.6 (Cipso), 130.0 (ArC), 130.1 (ArC), 132.3 (C(4)ArC(3)), 135.3 (C(3)ArC(1)), 
135.7 (SO2ArC(1)), 138.8 (C(3)ArC(4)), 145.7 (SO2ArC(4)), 165.4 (C(2)); m/z (NSI
+
) 489 
([M+NH4]
+
, 100%); HRMS (NSI+) C23H24BrN2O3S
+
 ([M+NH4]
+
), requires 487.0682; found 
487.0686 (−0.7 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(4-methoxyphenyl)-1-tosylazetidin-2-one 15  
The title compound was prepared according to General Procedure A from p-methoxyphenylacetic 
acid (33.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
mmol), 12 (10 mg, 20 mol%, 0.04 mmol), imine 8 (70.8 mg, 0.20 mmol) and purified by 
chromatography (20:80 EtOAc:Petrol) to afford the -lactam 15 as a white solid (62.0 mg, 67%); mp 
32-36 C;  −30.0 (c 1.0 in CH2Cl2); chiral HPLC analysis, Chiralcel OD-H (10% iPrOH:hexane, 
flow rate 1.0 mL min
-1
, 211 nm, rt), tR minor: 33.4 min, tR major: 42.0 min, 86% ee; νmax (film)/cm
-1
 
1792 (C=O), 1514, 1167 (R-SO2N); δH (400 MHz, CDCl3) 2.47 (3H, s, NSO2ArCH3), 3.77 (3H, s, 
OCH3), 4.19 (1H, d, J 3.4, C(3)H), 4.85 (1H, d, J 3.4, C(4)H), 6.01 (2H, d J 8.8, ArH), 6.93 (2H, d J 
8.5, ArH), 7.15 (2H, d, J 8.3, ArH), 7.31 (2H, m, ArH), 7.45 (2H, d, J 8.5, ArH), 7.73 (2H, d, J 8.3, 
ArH); C (100 MHz, CDCl3) 21.9 (NSO2ArCH3), 55.5 (OCH3), 64.1 (C(3)), 65.6 (C(4)), 114.8 (ArC), 
123.2, (Cipso), 124.6 (Cipso), 127.7 (ArC), 128.2 (ArC), 128.6 (ArC), 130.1 (ArC), 132.3 (ArC), 135.4 
(Cipso), 135.7 (Cipso), 145.7 (NSO2ArC(4)CH3), 159.8 (C(3)ArC(4)OMe), 165.7 (C(2)); m/z (NSI
+
) 
505 ([M+NH4]
+
, 100%); HRMS (NSI+) m/z [M+H]
+ 
calculated for C23H21BrNO4S
+
 486.0368; found 
486.0369 (−0.2 ppm). 
 
(3S,4S)-4-(4-Bromophenyl)-3-(phenylthio)-1-tosylazetidin-2-one 16 
The title compound was prepared according to General Procedure A from (phenylthio)acetic acid 
(33.6 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
mmol), 12 (10 mg, 20 mol%, 0.04 mmol),  imine 8 (70.8 mg, 0.20 mmol) and purified by 
chromatography (10:90 EtOAc:Petrol) to afford the -lactam 16 as a white solid (40.7 mg, 42% as a 
mixture of syn:anti 85:15); Anti: isolated white solid (8.3 mg, 14%); mp 78-84 C;  +7.0 (c 0.1 
in CHCl3); chiral HPLC analysis, Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 
nm, 30 C), tR major: 16.1 min, tR minor: 20.8 min, 61% ee; νmax (film)/cm
-1
 1790 (C=O), 1366 (C-N), 
1170 (R-SO2N); δH (400 MHz, CDCl3) 2.46 (3H, s, NSO2ArCH3), 4.11 (1H, d, J 3.2, C(3)H), 4.70 
(1H, d, J 3.2, C(4)H), 7.12-7.24 (2H, m, ArH), 7.21-7.30 (5H, m, ArH), 7.42-7.47 (4H, m, ArH), 
7.57-7.59 (2H, m, ArH); C (100 MHz, CDCl3) 21.9 (NSO2ArCH3), 61.5 (C(3)), 63.6 (C(4)), 123.5 
22
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(CBr), 127.9 (Ph), 128.1 (Ph), 128.6 (ArC), 129.3 (ArC), 129.6 (ArC), 130.1 (ArC), 132.3 (ArC), 
134.5 (ArC), 134.5 (Cipso), 135.3 (Cipso), 145.6 (CMe), 163.2 (C(2)); m/z (ESI
+
) 512 ([M+Na]
+
, 
100%); HRMS (NSI+) m/z [M+Na]
+ 
calculated for C22H18BrNO3S2
+
 509.9798; found 509.9804 (−1.1 
ppm). Syn: from mixture of diastereoisomers, selected data δH (400 MHz, CDCl3) 2.49 (3H, s, 
NSO2ArCH3), 4.79 (2H, d, J 6.4, CH), 5.35 (2H, d, J 6.1, CH), 6.99-7.02 (2H, m, ArH), 7.71-7.76 
(2H, m, ArH); chiral HPLC analysis, Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 
211nm, 24C), tR major: 25.9 min, tR major: 33.6 min, 62% ee. 
 
(2S,3R)-Methyl-3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-phenylpropanoate 17  
The title compound was prepared according to General Procedure B from phenylacetic acid (27 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 55 eq, 11 mmol), imine 8 (70.8 
mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 17 as a 
white solid (49.0 mg, 50%); mp 156-159 C;  −24.3 (c 1 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 29.0 min, tR 
major: 42.7 min, 99% ee; max (film)/cm
-1 
3237 (NH), 1740 (C=O), 1331 (R-SO2N), 1153 (R-SO2N); 
H (400 MHz, CDCl3) 2.35 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 3.92 (1H, d, J 6.45, C(2)H), 4.80 
(1H, dd, J 8.82, 6.53, C(3)H), 5.98 (1H, d, J 8.64, NH), 6.89-6.91 (2H, m, C(3)ArC(2)H), 7.01 (2H, d, 
J 7.95, C(3)NHSO2ArC(3)H), 7.13-7.16 (2H, m, ArH), 7.20-7.23 (5H, m, ArH), 7.33 (2H, d, J 8.29, 
C(3)NHSO2Ar(2)H); C (100 MHz, CDCl3) 21.6 (ArCH3), 52.6 (OCH3), 57.5 (C(2)), 60.6 (C(3)), 
121.7 (ArCBr), 127.0 (C(3)NHSO2ArC(2)), 128.1 (ArC), 128.6 (ArC), 128.7 (ArC), 128.9 
(C(3)ArC(2)), 129.3 (C(3)NHSO2ArC(3)), 131.5 (ArC), 134.5 (C(2)ArC(1)), 137.5 
(C(3)NHSO2ArC(1)), 137.8 (C(3)ArC(1)), 143.1 (C(3)NHSO2ArC(4)), 172.2 (C(1)); m/z (NSI
+
) 507 
([M+NH4]
+
, 100%); HRMS (NSI+) m/z [M+H]
+ 
calculated for C23H23BrNO4S
+
 488.0523; found 
488.0526 (−0.5 ppm). 
 
(2S,3R)-Methyl-3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(o-tolyl)propanoate 18 
The title compound was prepared according to General Procedure B from o-tolylacetic acid (150 mg, 
1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 portions of iPr2NEt (260 L, 1.50 mmol), 7 (15.5 
mg, 5 mol%, 0.05 mmol), nBuLi (2.5 M) solution in hexanes (0.5 mL, 55 mmol), imine 8 (354.0 mg, 
1.0 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 18 as a white 
solid (304.5 mg, 61%); mp 124-128 C;  −17.2 (c 0.25 in CHCl3); chiral HPLC analysis, 
22
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ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 16.7 min, tR 
major: 24.2 min, 76% ee; max (film)/cm
-1
 3246.2 (NH), 1746 (C=O), 1163 (R-SO2N); H (400 MHz, 
CDCl3) 2.20 (3H, s, C(2)ArCH3), 2.34 (3H, s, C(3)NHSO2ArCH3), 3.59 (3H, s, OCH3), 4.20 (1H, d, 
J 6.8 Hz, C(2)H), 4.76 (1H, dd, J 8.7, 6.8, C(3)H), 6.30 (1H, d, J 8.8, NH), 6.93-6.96 (2H, m, 
C(3)ArC(2)H), 6.99-7.02 (3H, m, ArH), 7.07-7.09 (2H, m, C(2)ArC(4)H & C(2)ArC(5)H), 7.19-7.21 
(2H, m, C(3)ArC(3)H), 7.26-7.28 (1H, m, C(2)ArC(6)H), 7.33 (2H, d, J 8.3, C(3)NHSO2ArC(2)H); 
C (100 MHz, CDCl3) 19.7 (C(2)ArC(2)CH3), 21.6 (C(3)NHSO2ArCH3), 52.5 (CH3O), 52.9 (C(2)), 
59.5 (C(3)), 121.6 (CBr), 126.5 (C(3)NHSO2ArC(2)), 126.9 (C(2)ArC(4)), 127.8 (C(2)ArC(6)), 
128.0 (C(2)ArC(5)), 128.7 (C(3)ArC(2)), 129.3 (ArC), 130.9 (ArC), 132.9 (C(3)ArC(3)), 133.0 
(C(2)ArC(1)), 135.9 (C(2)ArC(2)), 137.4 (C(3)ArC(1)), 138.0 (C(3)NHSO2ArC(1)), 143.0 
(C(3)NHSO2ArC(4)), 172.6 (C(1)); m/z (NSI
+
) 521 ([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C24H25BrNO4S
+
 502.0682; found 502.0682 (−0.0 ppm). This was recrystallised from 
CH2Cl2/Petrol to give the -lactam as a white solid (209.7 mg, 42%); mp 116-120 ˚C;  −12.0 (c 
0.5 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 
211 nm, 30 C), tR minor: 16.7 min, tR major: 24.2 min, 97% ee. 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-phenyl-2-(m-tolyl)propanoate 19  
The title compound was prepared according to General Procedure B from m-tolylacetic acid (30 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 8 (70.8 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 19  as a 
white solid (40.7 mg, 40%); mp 124-130 C;  −25.0 (c 0.1 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 39.9 min, tR 
major: 42.8 min, 74% ee; max (film)/cm
-1
 3248.1 (NH), 1736 (C=O), 1159 (R-SO2N); H (400 MHz, 
CDCl3) 2.23 (3H, s, C(2)ArC(3)CH3), 2.34 (3H, s, C(3)NHSO2ArCH3), 3.60 (3H, s, OCH3), 3.90 (1H, 
d, J 6.6, C(2)H), 4.79 (1H, dd, J 8.9, 6.7, C(3)H), 6.14 (1H, d, J 8.9, NH), 6.91-6.93 (4H, m, ArH), 
7.00 (3H, d, J 7.9, ArH), 7.07 (1H, t, J 7.9, C(2)ArC(3)H), 7.22 (2H, d, J 8.5, ArH), 7.32 (2H, d, J 
8.3, ArH); C (100 MHz, CDCl3) 21.5 (C(2)ArC(3)CH3), 21.6 (C(3)NHSO2ArCH3), 52.6 (OCH3), 
57.4 (C(2)), 60.6 (C(3)), 121.6 (CBr), 125.6 (C(3)ArC(2)), 126.9 (ArC), 128.7 (2×ArC), 128.8 (ArC), 
129.2 (ArC), 129.3 (ArC), 131.4 (ArC), 134.4 (C(2)ArC(1)), 137.6 (C(3)NHSO2ArC(1)), 138.0 
(C(3)ArC(1)), 138.5 (C(2)ArC(3)), 143.0 (C(3)NHSO2ArC(4)), 172.3 (C(1)); m/z (NSI
+
) 214 (100%), 
519 ([M+NH4]
+
, 40%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C24H25BrNO4S
+
 502.0681; found 
502.0682 (−0.2 ppm). 
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 (2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(p-tolyl)propanoate 20  
The title compound was prepared according to General Procedure B from p-tolylacetic acid (30 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 8 (70.8 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 20 as a white 
solid (45.8 mg, 46%); mp 163-168 C;  −26.0 (c 0.25 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 0.5 mL min
-1
, 211 nm, 30 C), tR major: 33.9 min, tR 
minor: 38.3 min, 87% ee; max (film)/cm
-1
 3252 (NH), 1736 (C=O), 1352.1 (R-SO2N), 1159.2 (R-
SO2N); H (400 MHz, CDCl3) 2.28 (3H, s, C(2)ArCH3), 2.35 (3H, s, C(3)NHSO2ArCH3), 3.59 (3H, s, 
OCH3),  3.89 (1H, d, J 6.5, C(2)H), 4.77 (1H, dd, J 8.8, 6.5, C(3)H), 6.03 (1H, d, J 8.8, NH), 6.91 
(2H, d, J 8.4, C(3)ArC(2)H), 6.99-7.02 (6H, m, ArH), 7.22 (2H, d, J 8.5, C(3)ArC(3)H), 7.33 (2H, d, 
J 8.3, C(3)NHSO2ArC(2)H); C (100 MHz, CDCl3) 21.3 (C(2)ArCH3), 21.6 (C(3)NHSO2ArCH3), 
52.5 (OCH3), 57.1 (C(2)), 60.6 (C(3)), 121.6 (ArCBr), 127.0 (C(3)NHSO2ArC(2)), 128.8 
(C(3)ArC(2)), 128.4 (ArC), 129.3 (C(3)NHSO2ArC(3)), 129.6 (ArC), 131.4 (C(2)ArC(1)), 131.5 
(C(3)ArC(3)), 137.6 (C(3)NHSO2ArC(1)), 137.9 (C(2)ArC(4)), 138.0 (C(3)ArC(1)), 143.0 
(C(3)NHSO2ArC(4)), 172.4 (C(1)); m/z (NSI
+
) 519 ([M+NH4]
+
, 45%), 526 (100%); HRMS (NSI
+
) 
m/z [M+H]
+ 
calculated for C24H25BrNO4S
+
 502.0681; found 502.0682 (−0.2 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-2-(naphthalene-1-yl)propanoate 21  
The title compound was prepared according to General Procedure B from 1-naphthylacetic acid (37.2 
mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 
(3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 8 (70.8 
mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 21 as a 
white solid (49.8 mg, 46%); mp 122-128C;  −12.2 (c 0.5 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 270 nm, 30 C), tR major: 24.9 min, tR 
minor: 30.6 min, 82% ee; max (film)/cm
-1
 3244.3 (NH), 1736 (C=O), 1331 (R-SO2N), 1157 (R-
SO2N); H (400 MHz, CDCl3) 2.24 (3H, s, ArCH3), 3.57 (3H, s, OCH3), 4.82 (1H, d, J 4.7, C(2)H), 
4.86-4.89 (1H, m, C(3)H), 6.47 (1H, d, J 8.7, NH), 6.74 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.07-
7.10 (2H, m, C(3)NHSO2ArC(2)H), 7.21-7.25 (2H, m, C(3)ArC(2)H), 7.27-7.37 (4H, m, ArH), 7.46-
7.58 (2H, m, ArH), 7.69 (1H, d, J 7.9, ArH), 7.79-7.82 (1H, m, ArH), 7.90 (1H, d, J 8.4, ArH); C 
(100 MHz, CDCl3) 21.5 (ArCH3), 52.2 (C(2)), 52.6 (OCH3),  58.7 (C(3)), 121.8 (CBr), 121.82 (ArC), 
22
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125.4 (ArC), 125.9 (ArC), 126.1 (ArC), 126.4 (C(3)NHSO2ArC(2)), 127.1 (ArC)), 128.5 
(C(3)ArC(2)), 128.9 (ArC), 129.0 (C(3)NHSO2ArC(3)), 129.5 (ArC), 130. 2 (Cipso), 130.7 (Cipso), 
131.75 (ArC), 134.2 (Cipso), 136.9 (C(3)NHSO2ArC(1)),  139.0 (C(3)ArC(1)), 142.6 (ArC(4)CH3), 
172.8 (C(1)); m/z (NSI
+
) 555 ([M+NH4]
+
, 45%), 562 (100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated 
for C27H25BrNO4S
+
 538.0680; found 538.0682 (−0.4 ppm).  
 
(2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(naphthalen-2-yl)propanoate  
22 
The title compound was prepared according to General Procedure B from 2-naphthylacetic acid 
(186.0 mg, 1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 portions of iPr2NEt (260 L, 1.50 
mmol), 7 (15.5 mg, 5 mol%, 0.05 mmol), nBuLi (2.5 M) solution in hexanes (0.5 mL, 55 mmol), 
imine 8 (354.0 mg, 1.0 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -
aminoester 22 as a white solid (368.5 mg, 68%); mp 164-170 C;  −35.8 (c 0.25 in CHCl3); 
chiral HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), 
tR major: 24.0 min, tR minor: 27.7 min, 85% ee; max (film)/cm
-1
 3210 (NH), 1711 (C=O), 1337 (R-
SO2N), 1163 (R-SO2N); H (400 MHz, CDCl3) 2.17 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 4.13 (1H, d, 
J 6.0, C(2)H), 4.87 (1H, dd, J 9.0, 5.9, C(3)H), 6.23 (1H, d, J 9.0, NH), 6.72 (2H, d, J 7.9, 
C(3)NHSO2ARC(3)H), 7.04-7.07 (2H, m, C(3)ArC(2)H), 7.20-7.23 (3H, m, ArH), 7.26-7.29 (2H, m, 
C(3)ArC(3)H), 7.46-7.49 (2H, m, ArH), 7.56 (1H, d, J 1.2, C(2)ArC(3)H), 7.60-7.63 (1H, m, ArH), 
7.67-7.70 (1H, m, ArH), 7.74-7.77 (1H, m, ArH); C (100 MHz, CDCl3) 21.5 (ArCH3), 52.6 (OCH3), 
57.3 (C(2)), 60.6 (C(3)), 121.8 (CBr), 126.0 (ArC), 126.5 (2×ArC), 126.6 (C(3)NHSO2ArC(2)), 
127.6 (C(2)ArC(3)), 127.7 (ArC), 128.1 (ArC), 128.6 (C(3)ArC(2)), 128.7 (C(3)ArC(2)), 129.1 
(C(3)NHSO2ArC(3)), 131.6 (C(3)ArC(3)), 131.9 (C(2)ArC(2)), 132.9 (Cipso), 133.2 (Cipso), 137.2 
(C(3)NHSO2ArC(1)), 138.3 (C(3)ArC(1)), 142.9 (ArC(4)CH3), 172.2 (C(1)); HRMS (NSI
+
) m/z 
[M+NH4]
+ 
calculated for C27H28BrN2O4S
+
 555.0945; found 555.0948 (−0.5 ppm). This was 
recrystallised from CH2Cl2/Petrol to give the -lactam as a white solid (222.2 mg, 41%); mp 106-112 
˚C;  −39.0 (c 0.5 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow 
rate 1.0 mL min
-1
, 220 nm, 30 C), tR major: 24.0 min, tR minor: 27.7 min, 91% ee. 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-2-(4-methoxyphenyl)-3-(4-methylphenylsulfonamido)propanoate 
23  
The title compound was prepared according to General Procedure B from p-methoxyphenylacetic 
acid (33.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
22
D][a
22
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mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 
8 (70.8 mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 
23 as a white solid (43.2 mg, 42%); mp 168-172 C;  −27.6 (c 0.5 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), tR major: 
24.1 min, tR minor: 27.1 min, 76% ee; max (film)/cm
-1
 3254 (NH), 1734 (C=O), 1157 (R-SO2N); H 
(400 MHz, CDCl3) 2.35 (3H, s, ArCH3),  3.60 (3H, s, C(1)(O)OCH3), 3.76 (3H, s, ArOCH3), 3.86 
(1H, d, J 6.66, C(2)H), 4.73-4.77 (1H, dd, J 8.79, 6.49, C(3)H), 5.97-5.99 (1H, d, J 8.89, NH), 6.69 
(2H, d, J 8.79, C(2)ArC(2)H), 6.89 (2H, d, J 8.62, C(3)ArC(2)H), 6.99-7.01 (2H, m, 
C(3)NHSO2ArC(3)H), 7.04 (2H, d, J 8.81, C(2)ArC(3)H), 7.21 (2H, d, J 8.52, C(3)ArC(3)H), 7.32-
7.34 (2H, m, C(3)NHSO2ArC(2)H); C (100 MHz, CDCl3) 21.6 (ArCH3), 52.5 (C(1)(O)OCH3), 55.3 
(ArOCH3), 56.6 (C(2)), 60.7 (C(3)), 114.2 (C(2)ArC(2)), 121.6 (CBr), 126.5 (C(2)ArC(1)), 127.0 
(C(3)NHSO2ArC(2)), 128.7 (C(3)ArC(2)), 129.3 (ArC), 129.6 (ArC), 131.5 (C(3)ArC(3)), 137.6 
(C(3)NHSO2ArC(1)), 137.9 (C(3)ArC(1)), 143.0 (ArC(4)CH3), 159.4 (ArC(4)OCH3), 172.5 (C(1)); 
m/z (NSI
+
) 535 ([M+NH4]
+
, 90%), 542 (100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for 
C24H25BrNO5S
+
 518.0630; found 518.0631 (−0.3 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-2-(4-fluorophenyl)-3-(4-methylphenylsulfonamido)propanoate 24  
The title compound was prepared according to General Procedure B from 4-fluorophenylacetic acid 
(30.8 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 
8 (70.8 mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 
24 as a white solid (56.5 mg, 56%); mp 138-144 C;  −22.2 (c 0.5 in CHCl3); chiral HPLC 
analysis, Chiralcel OD-H (20% iPrOH:hexane, flow rate 0.5 mL min
-1
, 211 nm, 30 C), tR minor: 
17.8 min, tR major: 22.4 min, 76% ee; max (film)/cm
-1 
3273 (NH), 1719 (C=O), 1153 (R-SO2N); H 
(400 MHz, CDCl3) 2.35 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 3.91 (1H, d, J 6.6, C(2)H), 4.75 (1H, dd, 
J 8.8, 6.8, C(3)H), 6.05 (1H, d, J 9.0, NH), 6.85 (2H, t, J 8.6, C(2)ArC(3)H), 6.90 (2H, d, J 8.4, 
C(3)ArC(2)H), 7.02 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.10 (2H, dd, J 8.6, 5.3, C(2)ARC(2)H), 
7.23 (2H, d, J 8.4, C(3)ArC(3)H), 7.34 (2H, d, J 8.2, NHSO2ARC(2)H); C (100 MHz, CDCl3) 21.5 
(ArCH3), 52.7 (OCH3), 56.6 (C(2)), 60.7 (C(3)),  115.8 (d, J 21.3, C(2)ArC(3)), 121.8 (CBr), 126.9 
(C(3)NHSO2ArC(2)), 128.6 (C(3)ArC(2)), 129.4 (C(3)NHSO2ArC(3)), 130.2 (d, J 7.5, C(2)ArC(2)), 
130.3 (d, J 3.8, C(2)ArC(1)), 131.6 (C(3)ArC(3)), 137.5 (C(3)ArC1)), 137.7 (C(3)NHSO2C(1)), 
143.3 (ArC(4)CH3), 162.5 (d, J 246.3, ArCF), 172.1 (C(1)); F (470 MHz, CDCl3)  (ArF);  m/z 
22
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(NSI
+
) 524 ([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C23H22BrFNO4S
+
 
506.0430; found 506.0431 (−0.3 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-2-(4-chlorophenyl)-3-(4-methylphenylsulfonamido)propanoate 25  
The title compound was prepared according to General Procedure B from 4-chlorophenylacetic acid 
(34.1mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 
7 (3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 8 (70.8 
mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 25 as a 
white solid (71.3 mg, 68%); mp 120-124 C;  −27.2 (c 0.5 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR major: 15.6 min, tR 
minor: 17.7 min, 78% ee; max (film)/cm
-1
 3304 (NH), 3258 (NH), 1736 (C=O), 1719 (C=O), 1153 
(R-SO2N), 1090 (C-Cl); H (400 MHz, CDCl3) 2.37 (3H, s,  CH3), 3.60 (3H, s, CH3OC(1)), 3.91 (1H, 
d, J 6.4, C(2)H), 4.74 (1H, dd, J 9.2, 6.4, C(3)H), 6.13 (1H, d, J 9.1, NH), 6.90-6.96 (2H, m, 
C(3)CCH), 6.99-7.08 (4H, m, ArH), 7.09-7.15 (2H, m, C(2)CCH), 7.23-7.29 (2H, m, CHCBr), 7.30-
7.36 (2H, m, SO2CCH); C (100 MHz, CDCl3) 21.3 (CH3), 52.4 (CH3C(1)), 56.3 (C(2)), 60.2 (C(3)), 
121.5 (CBr), 126.7 (SO2CArC), 128.4 (C(3)CArCH), 128.8 (ArC), 129.2 (C(2)CCH), 129.6 (ArC), 
131.5 (ArCCBr), 132.7 (C(2)ArC), 133.9 (ArCCl), 137.1 (SO2C), 137.4 (C(3)ArC), 143.0 (ArCCH3), 
171.6 (C(1)(O)); m/z (NSI
+
) 522 ([M+NH4]
+
, 50%), 546 (100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C23H22BrClNO4S
+
 522.0134; found 522.0136 (−0.4 ppm). 
 
(2S,3R)-Methyl 2,3-bis(4-bromophenyl)-3-(4-methylphenylsulfonamido)propanoate 26  
The title compound was prepared according to General Procedure B from 4-bromophenylacetic acid 
(43.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 
8 (70.8 mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 
26 as a white solid (49.6 mg, 43%); mp 168-172 C;  −28.0 (c 1.0 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), tR major: 
15.7 min, tR minor: 18.5 min, 98% ee; max (film)/cm
-1
 3368 (NH), 3298 (NH), 1719 (C=O), 1709 
(C=O), 1339 (R-SO2N), 1155 (R-SO2N); H (400 MHz, CDCl3) 2.38 (3H, s, ArCH3), 3.59 (3H, s, 
OCH3), 3.90 (1H, d, J 6.3, C(2)H), 4.73 (1H, dd, J 9.1, 6.3, C(3)H), 6.09 (1H, d, J 9.1, NH), 6.94-
6.96 (2H, m, C(3)ArC(2)H), 6.99-7.01 (2H, m, C(2)ArC(2)H), 7.02-7.05 (2H, m, ArH), 7.24-7.26 
(1H, m, ArH), 7.27-7.29 (3H, m, ArH), 7.31-7.33 (2H, m, C(3)NHSO2ArC(2)H); C (100 MHz, 
22
D][a
22
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CDCl3) 21.7 (ArCH3), 52.7 (OCH3), 56.7 (C(2)), 60.5 (C(3)), 121.9 (C(3)ArC(4)Br), 122.4 
(C(2)ArC(4)Br), 126.8 (C(3)NHSO2ArC(2)), 128.6 (C(3)ArC(2)), 129.4 (C(2)ArC(2)), 130.1 
(C(3)NHSO2ArC(3)), 131.7 (C(3)ArC(3)), 131.9 (C(2)ArC(3)), 133.6 (C(2)ArC(1)), 137.4 
(C(3)NHSO2ArC(1)), 137.7 (C(3)ArC(1)), 143.4 (ArC(4)CH3), 171.9 (C(1)); m/z (NSI
+
) 582 
([M+NH4]
+
, 35%), 589 (100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C23H22Br2NO4S
+
 
565.9630; found 565.9631 (−0.1 ppm). 
 
(2S,3R)-Methyl 
2-([1,1'-biphenyl]-4-yl)-3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)propanoate 27  
The title compound was prepared according to General Procedure B from biphenylacetic acid (42.4 
mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 
(3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 8 (70.8 
mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 27 as a 
white solid (49.7 mg, 44%); mp 148-154 C;  −45.5 (c 0.5 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), tR major: 39.4 min, tR 
minor: 50.3 min, 73% ee; max (film)/cm
-1
 3306 (NH), 1719 (C=O), 1153 (R-SO2N); H (400 MHz, 
CDCl3) 2.20 (3H, s, ArCH3), 3.63 (3H, s, OCH3), 4.00 (1H, d, J 6.5, C(2)H), 4.84 (1H, dd, J 9.1, 6.5, 
C(3)H), 6.23 (1H, d, J 9.1, NH), 6.93-7.01 (4H, m, ArH), 7.16-7.22 (2H, m, C(3)NHSO2ArC(3)H), 
7.22-7.26 (2H, m, C(3)ArC(3)H), 7.31-7.36 (3H, m, ArH), 7.36-7.48 (4H, m, ArH), 7.50-7.57 (2H, m, 
ArH); C (100 MHz, CDCl3) 21.4 (ArCH3), 52.6 (OCH3), 57.1 (C(2)), 60.7 (C(3)), 121.2 (CBr), 
127.0 (NHSO2ArC(2)), 127.2 (ArC), 127.4 (ArC), 127.7 (ArC), 128.7 (ArC), 128.9 (ArC), 129.0 
(ArC), 129.2 (NHSO2ArC(3)), 131.5 (C(3)ArC(3)), 133.5 (Cipso), 137.6 (C(3)NHSO2ArC(1)), 138.0 
(C(3)ArC(1)), 140.2 (C(2)ArC(1)), 140.8 (Cipso), 143.1 (ArC(4)CH3), 172.3 (C(1)); m/z (NSI
+
) 581 
([M+NH4]
+
, 70%), 588 (100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C29H27BrNO4S
+
 564.0838; 
found 564.0839 (−0.1 ppm). 
 
(2S,3S)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(phenylthio)propanoate 28  
The title compound was prepared according to General Procedure B from (phenylthio)acetic acid 
(33.6 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 
8 (70.8 mg, 0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 
28 as a white solid and a mixture of diastereoisomers (73.8 mg, 71%); Anti: isolated white solid (8.3 
mg, 14%); mp 120-124 C;  +6.0 (c 0.2 in CHCl3); chiral HPLC analysis, ChiralPak AD-H 
22
D][a
22
D][a
(20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), tR major: 20.4 min, tR minor: 24.7 min, 
61% ee; max (film)/cm
-1 
3289 (NH), 1711 (C=O), 1339 (R-SO2N), 1159 (R-SO2N); H (400 MHz, 
CDCl3) 2.37 (3H, s, ArCH3), 3.52 (3H, s, OCH3), 3.85 (1H, d, J 5.3, C(2)H), 4.82 (1H, dd, J 8.8, 5.3, 
C(3)H), 6.18 ( 1H, d, J 8.8, NH), 6.90 (2H, d, J 8.4, C(3)ArC(2)H), 7.10-7.15 (2H, m, 
C(3)NHSO2ArC(3)H), 7.25-7.31 (7H, m, ArH), 7.53-7.55 (2H, m, C(3)NHSO2ArC(2)H); C (100 
MHz, CDCl3) 21.6 (ArCH3), 52.7 (OCH3), 56.8 (C(2)), 58.7 (C(3)), 122.2 (CBr), 127.3 
(C(3)NHSO2ArC(3)), 128.6 (C(3)ArC(2)), 128.8 (ArC), 129.4 (C(3)NHSO2ArC(2)), 129.5 (ArC), 
131.7 (C(3)ArC(3)), 132.8, SArC(1)), 133.3 (ArC), 136.8 (C(3)ArC(1), 137.6 (SO2ArC(1)), 143.5 
(ArC(4)CH3), 170.9 (C(1)); m/z (NSI
+
) 537 ([M+NH4]
+
, 75%), 544 (100%); HRMS (NSI
+
) m/z 
[M+Na]
+ 
calculated for C23H22BrNO4S2Na
+
 542.0060; found 542.0066 (−1.1 ppm). Syn: isolated as a 
colourless oil (6.2 mg, 8%), selected data: δH (400 MHz, CDCl3) 2.41 (3H, s, ArCH3), 3.50 (3H, s, 
OCH3), 3.80 (1H, d, J 9.1, C(2)H), 4.55-4.58 (1H, m, C(3)H), 5.70-5.75 (1H, m, NH), 6.97-7.00 (2H, 
m, C(3)ArC(2)H), 7.13-7.16 (2H, m, C(3)NHSO2ArC(3)H), 7.22-7.24 (2H, m, C(3)ArC(3)H), 7.32-
7.43 (5H, m, ArH), 7.43-7.46 (2H, m, C(3)NHSO2ArC(2)H); C (100 MHz, CDCl3) 21.7 (ArCH3), 
52.6 (OCH3), 56.9 (C(2)), 57.3 (C(3)), 122.5 (CBr), 127.4 (C(3)NHSO2ArC(2)), 129.2 (ArC), 129.5 
(C(3)NHSO2ArC(3)), 129.5 (ArC), 129.9 (C(3)ArC(2)), 130.8 (SArC(1)), 131.4 (C(3)ArC(3)), 134.0 
(ArC), 135.7 (C(3)ArC(1)), 136.9 (SO2ArC(1)), 143.7 (ArC(4)CH3),169.1 (C(1));  −7.0 (c 0.1 
in CHCl3); chiral HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 
220nm, 30C), tR major: 30.6 min, tR minor: 38.4 min, 57% ee. 
 
(2R,3S)-Methyl 3-(4-methylphenylsulfonamido)-2,3-diphenylpropanoate 29  
The title compound was prepared according to General Procedure B from phenylacetic acid (136.0 
mg, 1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 portions of iPr2NEt (260 L, 1.50 mmol), 7 
(15.5 mg, 5 mol%, 0.05 mmol), nBuLi (2.5 M) solution in hexanes (0.5 mL, 55 mmol), imine S1 
(259.5 mg, 1.0 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 29 
as a white solid (219.3 mg, 54%); mp 162-165 C;  −25.6 (c 0.5 in CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (10% iPrOH:hexane, flow rate 0.5 mL min
-1
, 211 nm, 30 C), tR minor: 
61.7min, tR major: 82.0 min, 77% ee; max (film)/cm
-1
 3283 (NH), 1715 (C=O), 1159 (R-SO2N); H 
(400 MHz, CDCl3) 2.30 (3H, s, ArCH3), 3.59 (3H, s, OCH3), 3.97 (1H, d, J 6.5, C(2)H), 4.85 (1H, dd, 
J 9.1, 6.5, C(3)H), 6.01 (1H, d, J 9.1, NH), 6.98 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.00-7.03 (2H, 
m, ArH), 7.10 (3H, m, ArH), 7.16-7.20 (5H, m, ArH), 7.34-7.36 (2H, m, C(3)NHSO2ArC(2)H); C 
(100 MHz, CDCl3) 21.5 (ArCH3), 52.5 (OCH3), 57.8 (C(2)), 61.2 (C(3)), 126.8 (ArC), 127.0 
22
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(C(3)NHSO2ArC(2)), 127.6 (ArC), 127.9 (ArC), 128.4 (ArC), 128.6 (ArC), 128.8 (ArC), 129.2 
(C(3)NHSO2ArC(3)), 134.9 (C(2)ArC(1)), 138.8 (C(3)NHSO2C(1)), 142.8 (ArC(4)CH3), 151.1 
(C(3)ArC(1)), 172.4 (C(1)); m/z (NSI
+
) 427 ([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C23H24NO4S
+
 410.1422; found 410.1421 (+0.4 ppm). This was recrystallised from 
CH2Cl2/Petrol to give the -lactam as a white solid (105.6 mg, 26%); mp 168-172 ˚C;  −30.8 (c 
0.5 in CHCl3); chiral HPLC analysis, ChiralPak AD-H (10% iPrOH:hexane, flow rate 0.5 mL min
-1
, 
211 nm, 30 C), tR minor: 61.7min, tR major: 82.0 min, 93% ee. 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-(naphthalen-2-yl)-2-phenylpropanoate 30  
The title compound was prepared according to General Procedure B from phenylacetic acid (27.2 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine 42 (61.9 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 30  as a 
white solid (50.3 mg, 55%) as a white solid; mp 164-170 C;  −24.4 (c 0.5 in CHCl3); chiral 
HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR 
minor: 18.5 min, tR major: 21.2 min, 95% ee;  max (film)/cm
-1
 3258 (NH), 1722 (C=O), 1165 (R-
SO2N); H (400 MHz, CDCl3) 2.08 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 4.09 (1H, d, J 6.7, C(2)H), 
5.03 (1H, dd, J 9.2, 6.7, C(3)H), 6.18 (1H, d, J 9.2, NH), 6.77-6.80 (2H, m, ArH), 7.04-7.26 (5H, m, 
ArH), 7.27-7.37 (4H, m, ArH), 7.39-7.43 (2H, m, ArH), 7.52-7.64 (2H, m, ArH), 7.69-7.72 (1H, m, 
ArH); C (100 MHz, CDCl3) 21.3 (ArCH3), 52.5 (OCH3), 57.7 (C(2)), 61.3 (C(3)), 124.3 (ArC), 
126.1 (ArC), 126.2 (ArC), 126.6 (ArC), 126.9 (ArC), 127.5 (ArC), 127.9 (ArC), 128.0 (ArC), 128.3 
(ArC), 128.7 (ArC), 128.8 (ArC), 129.1 (ArC), 132.7 (Cipso), 132.9 (Cipso), 134.8 (Cipso), 135.6 (Cipso), 
137.6 (Cipso), 142.8 (ArC(4)CH3), 172.5 (C(1)); m/z (NSI
+
) 477 ([M+NH4]
+
, 80%), 482 (100%); 
HRMS (NSI
+
) m/z [M+Na]
+ 
calculated for C27H25NO4SNa
+
 482.1387; found 482.1397 (−2.0 ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-(naphthalen-1-yl)-2-phenylpropanoate 31  
The title compound was prepared according to General Procedure B from phenylacetic acid (27.2 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine S5 (61.9 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 31 as a white 
solid (57.6 mg, 63%); mp 122-128 C;  −30.4 (c 0.5 in CHCl3); chiral HPLC analysis, Chiralcel 
OD-H (5% iPrOH:hexane, flow rate 0.4 mL min
-1
, 211 nm, 30 C), tR minor: 80.1 min, tR major: 
22
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22
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22
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101.2 min, 56% ee;  max (film)/cm
-1
 3287 (NH), 1721 (C=O), 1161 (R-SO2N); H (400 MHz, CDCl3) 
2.21 (3H, s, ArCH3), 3.53 (3H, s, OCH3), 4.23 (1H, d, J 5.0, C(2)H), 5.62 (1H, dd, J 9.2, 5.0, C(3)H), 
6.63 (1H, d, J 9.0, NH), 6.72-6.86 (2H, m, ArH), 7.15-7.25 (6H, m, ArH), 7.30-7.38 (3H, m, ArH), 
7.48 (1H, ddd, J 8.0, 6.8, 1.2, ArH), 7.56 (1H, ddd, J 8.5, 6.8, 1.5, ArH), 7.64 (1H, d, J 8.1, ArH), 
7.75-7.83 (1H, m, ArH), 8.00 (1H, d, J 8.5, ArH); C (100 MHz, CDCl3) 21.3 (ArCH3), 52.5 (OCH3), 
57.6 (C(2)), 61.3 (C(3)), 124.3 (ArC), 126.2 (ArC), 126.3 (ArC), 126.6 (ArC), 126.9 (ArC), 127.6 
(ArC), 127.9 (ArC), 128.0 (ArC), 128.3 (ArC), 128.7 (ArC), 128.8 (ArC), 129.1 (ArC), 132.7 (Cipso), 
133.0 (Cipso), 134.8 (Cipso), 135.7 (Cipso), 137.6 (Cipso), 142.8 (ArC(4)CH3), 172.5 (C(1)); m/z (NSI
+
) 
477 ([M+NH4]
+
, 80%), 482 (100%); HRMS (NSI
+
) m/z [M+Na]
+ 
calculated for C27H25NO4SNa
+
 
482.1387; found 482.1397 (−2.0 ppm). 
 
(2S,3R)-Methyl 3-(furan-2-yl)-3-(4-methylphenylsulfonamido)-2-phenylpropanoate 32  
The title compound was prepared according to General Procedure B from phenylacetic acid (27.2 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine S4 (53.6 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 32 as a white 
solid (43.7 mg, 55%); mp 154-160 C;  −4.6 (c 0.5 in CHCl3); chiral HPLC analysis, Chiralcel 
OJ-H (10% iPrOH:hexane, flow rate 0.5 mL min
-1
, 211 nm, 30 C), tR major: 45.3 min, tR minor: 
53.9 min, 69% ee; max (film)/cm
-1 
3264 (NH), 1726 (C=O), 1163 (R-SO2N); H (400 MHz, CDCl3) 
2.43 (3H, s, ArCH3), 3.65 (3H, s, OCH3), 4.12 (1H, d, J 7.1, C(2)H), 4.97 (1H, dd, J 9.7, 7.1, C(3)H), 
5.66 (1H, d, J 9.8, NH), 5.84 (1H, d, J 3.3, C(3)ArC(3)H), 6.04 (1H, dd, J 3.2, 1.8, C(3)ArC(4)H), 
7.09 (2H, d, J 8.0, NHSO2ArC(3)H), 7.13 (3H, dd, J 9.3, 1.2, ArH), 7.20 (3H dd, J 4.8,2.4, ArH), 
7.46 (2H, d, J 8.2, SO2ArC(2)H); C (100 MHz, CDCl3) 21.6 (ArCH3), 52.5 (OCH3), 55.0 (C(2)), 
55.4 (C(3)), 108.4 (ArC), 110.4 (ArC), 127.0 (ArC), 128.0 (ArC), 128.6 (C(3)NHSO2ArC(3)),  128.7 
(C(2)ArC(1)), 129.4 (C(3)NHSO2ArC(1)), 134.4 (ArC), 137.7 (C(3)NHSO2ArC(1)), 142.0 
(C(3)NHSO2ArC(4)), 143.0 (ArC(4)CH3), 151.1 (C(3)ArC(1)), 172.0 (C(1)); m/z (NSI
+
) 229 (100%), 
417 ([M+NH4]
+
, 55%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C21H22NO5S
+
 400.1209; found 
400.1213 (−1.0 ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-2-phenyl-3-(4-(trifluoromethyl)phenyl)propanoate 33 
The title compound was prepared according to General Procedure B from phenylacetic acid (27.2 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine S3 (65.5 mg, 
22
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0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 33 as a white 
solid (46.4 mg, 49%); mp 118-124 C;  −17.6 (c 0.5 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 15.9 min, tR 
major: 20.9 min, 47% ee; max (film)/cm
-1
 3237 (NH), 1742 (C=O), 1323 (R-SO2N), 1161 (R-SO2N), 
1117 (CF3); H (400 MHz, CDCl3) 2.28 (3H, s, ArCH3), 3.64 (3H,s, OCH3), 3.96 (1H, d, J 7.3, 
C(2)H), 4.94 (1H, dd, J 9.1, 7.3, (C(3)H), 6.34 (1H, d, J 9.1, NH), 6.95 (2H, d J 8.3, 
C(3)NHSO2ArC(3)H), 7.07-7.10 (2H, m, ArH), 7.16-7.19 (5H, m, ArH), 7.29-7.34 (4H, m, ArH); C 
(100 MHz, CDCl3) 21.4 (ArCH3), 52.7 (OCH3), 57.6 (C(2)), 60.8 (C(3)), 124.0 (q, J 271.3, CF3), 
125.2 (q, J 5, C(3)ArC(3)), 126.9 (ArC), 127.6 (ArC), 128.2 (ArC), 128.6 (ArC), 128.9 (ArC), 129.3 
(ArC), 129.7 (q, J 36.6, C(3)ArC(4)CF3), 134.3 (C(2)ArC(1)), 137.4 (C(3)NHSO2ArC(1)), 142.4 
(C(3)ArC(1)), 143.2 (C(3)NHSO2ArC(4)CH3), 172.2 (C(1)); F (470 MHz, CDCl3)  (CF3); m/z 
(NSI
+
) 495 ([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+H]
+ 
calculated C24H23F3NO4S
+
 478.1289; 
found 478.1294 (−1.1 ppm). 
 
(2S,3R)-Methyl 3-(4-nitrophenylsulfonamido)-2,3-diphenylpropanoate 34  
The title compound was prepared according to General Procedure B from phenylacetic acid (27.2 mg, 
0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 7 (3.1 
mg, 5 mol%, 0.01 mmol), nBuLi (2.5 M) solution in hexanes (0.1 mL, 11 mmol), imine S6 (58.1 mg, 
0.20 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -aminoester 34 as a white 
solid (47.4 mg, 54%); mp 158-162 C;  −20.8 (c 0.5 in CHCl3); chiral HPLC analysis, Chiralcel 
OD-H (10% iPrOH:hexane, flow rate 0.5 mL min
-1
, 211 nm, 30 C), tR minor: 63.7 min, tR major: 
106.7 min, 75% ee;  max (film)/cm
-1 
3240 (NH), 1740 (C=O), 1390 (NO2), 1323 (RSO2N), 1161 
(RSO2N); H (400 MHz, CDCl3) 3.60 (s, 3H, OCH3), 4.02 (1H, d, J 5.4, C(2)H), 4.86 (1H, dd, J 9.2, 
5.4, C(3)H), 6.59 (1H, d, J 9.2, NH), 7.09-7.12 (3H, m, ArH), 7.14-7.23 (7H, m, ArH), 7.58 (2H, d, J 
8.8, NHSO2ArC(2)H), 7.98 (2H, d, J 8.8, NHSO2ArC(3)H); C (125 MHz, CDCl3) 52.6 (OCH3), 57.1 
(C(2)), 61.7 (C(3)), 123.8 (NHSO2ArC(3)), 126.7 (ArC), 128.0 (ArC), 128.1 (ArC), 128.2 (ArC), 
128.3 (ArC), 128.7 (ArC), 129.0 (NHSOArC(2)), 134.8 (NHSO2ArC(1)), 138.5 (Cipso), 146.5 (Cipso), 
149.4 (CNO2), 172.6 (C(1)); m/z (NSI
+
) 458 ([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+NH4]
+ 
calculated for C22H24N3O6S
+
 458.1382; found 458.1380 (+0.4 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(2-napthylene)-1-tosylazetidin-2-one 36  
22
D][a
22
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The title compound was prepared according to General Procedure C from imine 8 (70.8 mg, 0.20 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), iPr2NEt (43.0 L, 0.25 mmol), 2-naphthoic anhydride (106.4 
mg, 0.30 mmol) and purified by chromatography (10:90 EtOAc:Petrol) to give -lactam 36 as a 
white solid (44.4 mg, 44%); mp 120-126 C;  −63.0 (c 0.5 in CHCl3); chiral HPLC analysis, 
Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 221 nm, 30 C), tR minor: 22.2 min, tR 
major: 28.4 min, 83% ee;  νmax (KBr)/cm
-1
 1774 (C=O), 1374 (C-N), 1173 (R-SO2N); δH (400 MHz, 
CDCl3) 2.50 (3H, s, NSO2ArCH3), 4.39 (1H, d, J 3.4, C(3)H), 4.98 (1H, d, J 3.3, C(4)H), 7.07 (1H, 
dd, J 8.5, 1.9, ArH), 7.21 (2H, d, J 8.3, ArH), 7.35 (2H, m, ArH), 7.47-7.53 (5H, m, ArH), 7.69-7.72 
(1H, m, ArH), 7.77-7.83 (4H, m, ArH); C (100 MHz, CDCl3) 21.8 (NSO2ArCH3), 64.5 (C(3)), 66.8 
(C(4)), 123.3 (ArC, CBr), 126.7 (2×ArC), 126.9 (ArC), 127.5 (ArC), 127.8 (ArC), 127.9 (ArC), 
128.2 (ArC), 128.6 (ArC), 129.2 (ArC), 129.4 (C(3)NHSO2ArC(2)), 130.0 (ArC), 133.0 (Cipso), 133.2 
(Cipso), 133.3 (Cipso), 135.9 (Cipso), 145.5 (NSO2ArC(4)CH3), 165.4 (C(2)); m/z (NSI
+
) 524 
([M+NH4]
+
, 100%); HRMS (NSI
+
) m/z [M+NH4]
+ 
calculated for C26H24BrN2O3S
+
 523.0674; found 
523.0686 (−2.2 ppm). 
 
 (3S,4R)-4-(4-Bromophenyl)-3-(thiophen-3-yl)-1-tosylazetidin-2-one 37  
The title compound was prepared according to General Procedure C from imine 8 (70.8 mg, 0.20 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), iPr2Net (43.0 L, 0.25 mmol), anhydride S9 (79.9 mg, 0.30 
mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -lactam 37 as a white solid 
(43.5 mg, 47%); mp 104-106 C;  +20.0 (c 0.5 in CHCl3); chiral HPLC analysis, Chiralcel OD-
H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 220 nm, 30 C), tR minor: 26.6 min, tR major: 34.1 
min, 82% ee;   νmax (film)/cm
-1
 3109 (thiophene CH), 1792 (C=O), 1487 (C-N), 1373 (R-SO2N), 1173 
(R-SO2N); δH (400 MHz, CDCl3) 2.47 (3H, s, NSO2ArCH3), 4.29 (1H, d, J 3.3, C(3)H), 4.87 (1H, d, 
J 3.3, C(4)H), 6.76 (1H, dd, J 5.0, 1.3, C(3)ArH), 7.08 (1H, dt, J 1.8, 0.9, C(3)ArH), 7.16-7.18 (2H, 
m, ArH), 7.31-7.34 (3H, m, ArH), 7.46-7.48 (2H, m, ArH), 7.72-7.74 (2H, m, ArH); C (100 MHz, 
CDCl3) 21.9 (NSO2ArCH3), 60.1 (C(3)), 64.9 (C(4)), 123.4 (C(3)ArC), 125.8 (C(3)ArC), 127.6 
(ArC), 127.7 (ArC), 128.2 (ArC), 130.1 (ArC), 132.1 (Cipso), 135.2 (Cipso), 135.5 (Cipso), 145.8 
(NSO2ArC(4)CH3), 164.9 (C(2)), 185.4 (Cipso); m/z (NSI
+
) 579 ([M+NH4]
+
, 85%), 481 (100%); 
HRMS (NSI
+
) m/z [M+NH4]
+ 
calculated for C20H17BrNO3S2
+
 461.9830; found 461.9828 (+0.5 ppm). 
 
(3S,4R)-4,3-Diphenyl-1-tosylazetidin-2-one 38  
22
D][a
22
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The title compound was prepared according to General Procedure C from imine S1 (338.0 mg, 1.0 
mmol), 7 (15.5 mg, 5 mol%, 0.05 mmol), iPr2NEt (215 L, 1.25 mmol), benzoic anhydride 35 (381.0 
mg, 1.5 mmol) and purified by chromatography (10:90 EtOAc:Petrol) to give -lactam 38 as a white 
solid (228.7 mg, 60%); chiral HPLC analysis, Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL 
min
-1
, 254 nm, 30 C), tR major: 14.8 min, tR minor: 19.6 min, 89% ee; δH (400 MHz, CDCl3) 2.45 
(3H, s, CH3), 4.27 (1H, d, J 3.4, C(3)H), 4.98 (1H, d, J 3.4, C(4)H), 7.06 (2H, m, PhH), 7.26-7.34 
(10H, m, PhH), 7.71 (2H, m, PhH). All NMR data was in accordance to the literature.
27a
 This was 
recrystallised from CH2Cl2/Petrol to give the -lactam as a white solid (129.5 mg, 34%); mp 91-98 
C {lit.Error! Bookmark not defined. mp 123-124 C};  +35.6 (c 0.5 in CHCl3); chiral HPLC analysis, 
Chiralcel OD-H (10% iPrOH:hexane, flow rate 1.0 mL min
-1
, 254 nm, 30 C), tR major: 14.8 min, tR 
minor: 19.6 min, >99% ee. 
 
(3S,4R)-4-(Naphthalene-2-yl)-3-phenyl-1-tosylazetidin-2-one 39  
The title compound was prepared according to General Procedure C from imine 42 (61.9 mg, 0.20 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), iPr2NEt (43.0 L, 0.25 mmol), benzoic anhydride 35 (76.2 
mg, 0.30 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -lactam 39 as a 
white solid (47.8 mg, 56%); mp 38-44 C;  −8.8 (c 0.25 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR major: 19.3 min, tR 
minor: 41.5 min, 92% ee; νmax (film)/cm
-1
 2920, 1792 (C=O), 1456 (C-N), 1364 (R-SO2N), 1166 (R-
SO2N); δH (400 MHz, CDCl3) 2.41 (3H, s, NSO2ArCH3), 4.36 (1H, d, J 3.0, C(3)H), 5.16 (1H, d, J 
3.0,  C(4)H), 7.11-7.14 (2H, m, ArH), 7.16-7.24 (2H, m, ArH), 7.31-7.35 (3H, m, ArH), 7.48-7.57 
(2H, m, ArH), 7.69- 7.72 (3H, m, ArH), 7.72-7.76 (2H, m, ArH), 7.80 (1H, d, J 8.5, ArH), 7.82-7.89 
(1H, m, ArH); C (100 MHz, CDCl3) 21.8 (NSO2ArCH3), 64.5 (C(3)), 66.2 (C(4)), 123.3 (ArC), 
126.7 (ArC), 126.9 (ArC), 127.0 (ArC), 127.4 (ArC), 127.8 (ArC), 127.9 (ArC), 128.2 (ArC), 128.6 
(ArC), 129.2 (ArC), 129.4 (ArC), 130.0 (ArC), 133.0 (Cipso), 133.1 (Cipso), 133.3 (Cipso), 133.6 (Cipso), 
135.8 (C(3)ArC(1)), 145.5 (NSO2ArC(4)CH3), 165.5 (C(2)); m/z (NSI
+
) 445 ([M+NH4]
+
, 100%); 
HRMS (NSI
+
) m/z [M+NH4]
+ 
calculated for C26H25N2O3S
+
 445.1578; found 445.1580 (0.5 ppm). 
Syn: from mixture of diastereoisomers, selected data δH (400 MHz, CDCl3) 2.43 (3H, s, NSO2ArCH3), 
5.04 (1H, J 6.8, CH), 5.65 (1H, J 6.9, CH); chiral HPLC analysis, ChiralPak AD-H (20% 
iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR major: 18.1 min, tR minor: 25.6 min, 54% 
ee. 
22
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 (3S,4R)-3-Phenyl-1-tosyl-4-(4-(trifluoromethyl)phenyl)azetidin-2-one 40  
The title compound was prepared according to General Procedure C from imine S3 (65.5 mg, 0.20 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), iPr2NEt (43.0 L, 0.25 mmol), benzoic anhydride 35 (76.2 
mg, 0.30 mmol) and purified by chromatography (20:80 EtOAc:Petrol) to give -lactam 40 as a 
white gum (41.9 mg, 47%);  +17.2 (c 0.5 in CHCl3); chiral HPLC analysis, Chiralcel OD-H 
(5% iPrOH:hexane, flow rate 0.25 mL min
-1
, 211 nm, 30 C), tR minor: 82.7 min, tR major: 90.2 min, 
68% ee; νmax (film)/cm
-1
 1796 (C=O), 1323 (R-SO2N), 1167 (R-SO2N); δH (400 MHz, CDCl3) 2.47 
(3H, s, NSO2ArCH3), 4.25 (1H, d, J 3.4, C(3)H), 5.00 (1H, d, J 3.4, C(4)H), 6.98-7.08 (2H, m, ArH),  
7.29-7.37 (5H, m, ArH), 7.40-7.43 (2H, m, ArH), 7.55-7.63 (2H, m, ArH), 7.73-7.76 (2H, m, ArH); 
δF (282 MHz, CDCl3) 62.7 (CF3); C (100 MHz, CDCl3) 21.9 (NSO2ArCH3), 64.6 (C(3)), 65.0 (C(4)), 
123.9 (q, J 217, CF3), 126.2 (q, J 3, C(4)ArC(3)), 126.9 (ArC), 127.4 (ArC), 127.7 (ArC), 128.8 
(ArC), 129.5 (ArC), 130.2 (ArC), 131.5 (q, J 26, C(4)ArC(4)CF3), 132.5 (Cipso), 135.5 (Cipso), 140.3 
(C(4)ArC(1)), 145.9 (NSO2ArC(4)CH3), 165.1 (C(1));
 
m/z (NSI
+
) 463 ([M+NH4]
+
, 100%); HRMS 
(NSI
+
) m/z [M+NH4]
+ 
calculated for C23H19BF3NO3S
+
 446.1031; found 446.1032 (−0.3 ppm). 
 
(3S,4R)-1-((4-Nitrophenyl)sulfonyl)-3,4-diphenylazetidin-2-one 41 
The title compound was prepared according to General Procedure C from imine S6 (58.1 mg, 0.20 
mmol), 7 (3.1 mg, 5 mol%, 0.01 mmol), iPr2NEt (43.0 L, 0.25 mmol), benzoic anhydride 35 (72.6 
mg, 0.30 mmol) and purified by chromatography (10:90 EtOAc:Petrol) to give -lactam 41 as a 
white solid (41.6 mg, 51%). mp 108-114 C;  −2.1 (c 0.9 in CHCl3); chiral HPLC analysis, 
ChiralPak AD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 28.3 min, tR 
major: 32.6 min, 85% ee;  νmax (KBr)/cm
-1
 1797 (C=O), 1529 (NO2), 1379 (C-N), 1176 (R-SO2N); δH 
(400 MHz, CDCl3) 4.42 (1H, d, J 3.45, C(3)H), 5.12 (1H, d, J 3.43, C(4)H), 7.17-7.20 (2H, m, ArH), 
7.24-7.25 (1H, m, ArH), 7.32-7.40 (7H, m, ArH), 7.92-7.97 (2H, m, NSO2ArC(2)H), 8.27-8.29 (2H, 
m, NSO2ArC(3)H); C (100 MHz, CDCl3) 64.2 (C(3)), 66.3 (C(4)), 124.3 (NSO2ArC(3)), 126.8 
(ArC), 127.0 (ArC), 128.6 (ArC), 128.8 (NSO2ArC(2)), 129.1 (ArC), 129.3 (ArC), 129.6 (ArC), 
132.2 (C(4)ArC(1)), 135.0 (C(3)ArC(1)), 144.1 (NSO2ArC(1)), 150.7 (NSO2ArC(4)), 164.8 (C(2)); 
22
D][a
22
D][a
m/z (APCI
+
) 409 ([M+H]
+
,100%); HRMS (APCI
+
) m/z [M+H]
+ 
calculated for C21H17N2O5S
+
 
409.0851; found 409.0853(−0.4 ppm). 
Detosylation reaction 
(3S,4R)-4-(4-Bromophenyl)-3-phenylazetidin-2-one S10 
Using a modified version of the procedure by Lectka et al.
41
 N-tosylazetidinone 9 (54.1 mg, 0.12 
mmol, 1 eq) was stirred in THF (1 mL) at rt and ~0.1 M SmI2 in THF (7.80 mL, 0.72 mmol, 6 eq) 
was added dropwise until the colour remained consistent. The reaction mixture was stirred for 5 min, 
quenched with NaHCO3 (5 mL), extracted (3 × EtOAc), dried (MgSO4) and concentrated in vacuo to 
give the crude product as a yellow oil. Following purification by column chromatography (40:60 
EtOAc:Petrol) -lactam S10 was isolated as a colourless oil (14.6 mg, 48%).  −55.6 (c 0.5 in 
CHCl3); chiral HPLC analysis, Chiralcel OD-H (20% iPrOH:hexane, flow rate 1.0 mL min
-1
, 211nm, 
25C), tR major: 29.2 min, tR minor: 38.9 min, 90% ee;  νmax (film)/cm
-1
 3263 (NH), 1751 (C=O); δH 
(400 MHz, CDCl3) 4.17 (1H, d, J 2.40, C(3)H), 4.65 (1H, d, J 2.40, C(4)H), 6.34 (1H, br s, NH), 
7.28-7.32 (4H, m, ArH), 7.34-7.39 (2H, m, ArH), 7.53-7.55 (2H, m, ArH); C (100 MHz, CDCl3) 
59.8 (C(3)), 66.4 (C(4)), 122.5 (CBr), 127.4 (ArC), 127.5 (ArC), 128.1 (ArC), 129.2 (ArC), 132.3 
(ArC), 134.5 (Cipso), 138.7 (Cipso), 168.8 (C(2)); m/z (NSI
+
) 324 (100%), 319 ([M+NH4]
+
, 85%); 
HRMS (NSI
+
) m/z [M+H]
+ 
calculated for C15H13BrNO
+
 302.0178; found 302.0175 (+1.0 ppm). 
Control Experiments 
Control Experiment 1 
-Lactam 39 was prepared according to General Procedure A from phenyl acetic acid (27.2 mg, 0.20 
mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of iPr2NEt (52 L, 0.30 mmol), 12 (10 mg, 
20 mol%, 0.04 mmol) and imine 42 (70.8 mg, 0.20 mmol). The reaction was monitored over time 
using 
1
H NMR for changes in the diastereomeric ratio. The results are shown in table Scheme 3. 
 
Control Experiment 2 
A sample of -lactam 39 (3.3 mg, 0.007 mmol) with of a known dr (anti:syn 21:79) and ees (anti 
90%, syn 52%) was dissolved in CH2Cl2 (1 mL) and treated with iPr2NEt (100 μL, 0.6 mmol) and 7 
(3.1 mg, 0.01 mmol). The reaction was stirred at rt for 3 h, quenched with 1M HCl, extracted 
(3×CH2Cl2), dried (MgSO4) and concentrated in vacuo to give the crude product (dr >95:5) with 
22
D][a
identical spectroscopic data as previously reported; chiral HPLC analysis, ChiralPak AD-H (20% 
iPrOH:hexane, flow rate 1.0 mL min
-1
, 211 nm, 30 C), tR minor: 19.3 min, tR major: 41.5 min, 32% 
ee. 
 
Control Experiment 3 
To a stirred solution of phenylacetic acid (27.2 mg, 1 eq, 0.20 mmol) in CH2Cl2 (1 mL) at 0 C, tosyl 
chloride (57.3 mg, 1.5 eq, 0.30 mmol) and iPr2NEt (52 L, 1.5 eq, 0.30 mmol) were added. The 
solution was stirred at 0 C for 20 min. The achiral isothiourea catalyst, 10 (7.6 mg, 20 mol%, 0.04 
mmol) and imine 8 (70.8 mg, 1 eq, 0.20 mmol) were added followed by 
i
Pr2NEt (52 L, 1.5 eq, 0.30 
mmol). The solution was then stirred at rt for 1 h before quenching with 1M HCl, extracted 
(3×EtOAc), drying the combined organic layers (MgSO4) and concentrating in vacuo. The resulting 
residue was redissolved in CH2Cl2 (1 mL) and treated with 7 (12.3 mg, 20 mol%), NaOMe (23.0 mg, 
2 eq, 0.40 mmol) and methanol (1 mL). The reaction mixture was stirred for 1 hour at rt before being 
quenched with water (1 mL), extracted (3×EtOAc), the combined organic layers dried (MgSO4) and 
concentrated in vacuo to give the crude product. Following purification by column chromatography 
(20:80 EtOAc:Petrol), 17 was obtained as a white solid (38.5 mg, 39%) with identical spectroscopic 
data as reported previously; chiral HPLC analysis, ChiralPak AD-H (20% iPrOH:hexane, flow rate 
1.0 mL min
-1
, 211 nm, 30 C), tR minor: 29.0 min, tR major: 42.7 min, 16% ee. 
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